Acute lymphoblastic leukemia (ALL) is the most common cancer in pediatric patients, with an overall 5-year survival of >90%.1 The length of treatment for these patients is typically 2 to 3 years and involves several phases (induction, consolidation, and maintenance) and multiple forms of chemotherapy. Read More ›